PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32541562-5	2021	As we enter the fourth decade of tacrolimus use, newer studies utilizing of novel combinations (as with the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and T-cell co-stimulation blockade with belatacept) offer potential for enhanced benefits.	Tacrolimus	33-43	mechanistic target of rapamycin kinase	Homo sapiens	108-137